Action Pharma sells drug to Abbott

Monday 7 May 2012

Action Pharma A/S has secured $110 million in cash from Abbott Laboratories Inc for its early-stage compound for the prevention of acute kidney injury associated with major cardiac surgery. The compound, AP214, had positive Phase 2b data.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark